Intelligence Feed event · Macro · 2026-09-05

    Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M

    Question

    Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M

    Direct answer

    Novartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-05
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M”, revision 1, evidence through 2026-09-05. https://marketontology.com/market-events/2026-09-05/novartis-pelacarsen-phase-3-trial-fails-royalty-pharma-expects-to-recoup-500m-dad871

    MACRO
    Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
    Novartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss.
    NVSRPRX
    Impact
    74
    SEP 5
    SIG
    88%
    NVSRPRX
    Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
    Novartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss.
    → A Phase 3 clinical trial failure eliminates downstream royalty revenue streams from pelacarsen for NVS and RPRX while capping capital loss for Royalty Pharma at its $500 million baseline investment.
    Impact
    Novartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss.
    Affected
    NVSRPRX
    Transmission
    A Phase 3 clinical trial failure eliminates downstream royalty revenue streams from pelacarsen for NVS and RPRX while capping capital loss for Royalty Pharma at its $500 million baseline investment.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    NVSpipeline net present value reductionDown1-5dPhase 3 HORIZON trial for pelacarsen failed to meet primary endpoint of reducing cardiovascular events.
    RPRXcapital recovery certainty vs lost upside royaltiesMixed1-5dRoyalty Pharma expects to recoup $500 million investment and earn modest positive return.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month